Akumentis Healthcare Launches Epilepsy Drug: Clasepi
By Rediff Money Desk, NEWDELHI Jan 10, 2024 15:58
Akumentis Healthcare launches Clasepi, a cannabidiol (CBD) drug for epilepsy treatment, targeting Lennox-Gastaut, Dravet, and Tuberous Sclerosis in patients aged 1 year and older.
New Delhi, Jan 10 (PTI) Akumentis Healthcare on Wednesday said it has introduced a drug for the treatment of epilepsy.
The Mumbai-based company has launched Clasepi, a DCGI-approved prescription cannabidiol (CBD) specifically formulated to address seizures linked with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older, it said in a statement.
Clinical studies have demonstrated Clasepi's efficacy in reducing seizures, especially in cases where conventional anti-seizure medications have proven ineffective, it added.
"We understand the immense physical and emotional toll that frequent seizures can have on patients and their families," Akumentis Executive Director Kanishk Jain said.
This is the driving force behind our commitment to developing novel solutions that effectively relieves the complexities of these disorders, he added.
According to the World Health Organisation (WHO), epilepsy constitutes a considerable portion of the global disease burden, affecting around 50 million people worldwide, with 20 per cent of patients residing in India.
The Mumbai-based company has launched Clasepi, a DCGI-approved prescription cannabidiol (CBD) specifically formulated to address seizures linked with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older, it said in a statement.
Clinical studies have demonstrated Clasepi's efficacy in reducing seizures, especially in cases where conventional anti-seizure medications have proven ineffective, it added.
"We understand the immense physical and emotional toll that frequent seizures can have on patients and their families," Akumentis Executive Director Kanishk Jain said.
This is the driving force behind our commitment to developing novel solutions that effectively relieves the complexities of these disorders, he added.
According to the World Health Organisation (WHO), epilepsy constitutes a considerable portion of the global disease burden, affecting around 50 million people worldwide, with 20 per cent of patients residing in India.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- ARC Finance
- 1.51 (+ 2.72)
- 99106131
- Vodafone Idea L
- 8.27 (+ 1.72)
- 37910491
- Guj. Toolroom Lt
- 18.98 (+ 4.98)
- 33052379
- Srestha Finvest
- 0.81 ( -2.41)
- 24087791
- Filatex Fashions
- 0.69 ( -4.17)
- 20455844
MORE NEWS
CCI Clears Coal India in E-Auction Scheme Case
India's competition watchdog CCI dismissed a complaint against Coal India's e-auction...
HDFC Bank Loan Growth Rises 3% in Q3
HDFC Bank reports a 3% increase in loan growth in the December quarter, reaching Rs...
IDBI Bank Reports 18% Loan Growth in Q3
IDBI Bank saw an 18% increase in loan growth during the December quarter, reaching Rs...